anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This study was performed to determine the consequences of conventional physical therapy with and without Mulligan's Squeeze technique for meniscal derangement treatment in patients with knee osteoarthritis. This research study was a randomized controlled trial. The sample size was of 26 subjects. The subjects were nominated in accordance to the inclusion and exclusion criteria. They were equally and randomly divided into two groups. One group received Mulligan's Squeeze technique along with conventional physiotherapy exercises, with hot pack prior to the exercise session. The control group was only given conventional therapy exercises with hot pack application prior to any exercise. The treatment was given for two weeks and a total of six sessions, three sessions each week. The primary outcome measures were Numerical Pain Rating Scale (NPRS) for pain rating and goniometer to record range of knee flexion. The secondary outcome measures were Patient-specific functional scale (PSFS) and Knee-injury osteoarthritis outcome score (KOOS). The measurements were taken at baseline, at end of first week and after the second week. The data was analyzed by using IBM SPSS software version 27.
Patients receive low-dose cyclophosphamide IV on day 0 and GVAX pancreatic cancer vaccine ID on day 1. Patients undergo pancreaticoduodenectomy on day 15. Approximately 6-10 weeks after surgery, patients receive low-dose cyclophosphamide IV on day 0 and the vaccine on day 1. Beginning approximately 1 month after vaccination, patients receive standard adjuvant chemoradiotherapy. Beginning approximately 4-8 weeks after the completion of chemoradiotherapy, patients receive low-dose cyclophosphamide IV on day 0 and the vaccine on day 1. Treatment with cyclophosphamide and the vaccine repeats every 28 days for 4 courses. Patients will then enter the extended treatment phase where they will receive cyclophosphamide on day 0, and GVAX on day 1 every 12 weeks for another 2 treatments.
PURPOSE: To reduce the trouble required for the generation, management, etc., of medical charts by holding a read partial picture in relation with given medical treatment data and recording those medical treatment data and partial picture as specific positions on a specific form. CONSTITUTION: For, for example, an oral surgical treatment, position registration data which are registered as medical chart data are read out and a position is specified with the read position registration data. Consequently, corresponding partial pictures are read out of a vertical teeth expansion picture file and a horizontal teeth expansion picture file recorded on a hard disk 13. The read partial pictures are displayed together with the registered medical chart data. A dentist deletes unnecessary pictures or writes additional contents of patient's conditions or a treatment. When the contents of the oral surgical treatment are confirmed, the contents of medication are recorded on the medical chart 14. Namely, a medication screen file is read out, its screen is displayed on a display 9, and the medical chart data are stored on a floppy disk 14.
PURPOSE:To provide the subject low toxic antagonistic agent capable of being orally for parenterally administered, exhibiting an excellent thromboxane A2- antagonistic activity and useful for the treatment of various diseases caused by the thromboxane by compounding a glycine derivative as an active ingredient. CONSTITUTION:The objective agent contains a glycine derivative of formula I [R<1> is (substituted) phenyl; one of R<2> and R<3> is lower alkyl and the other is H; R<4> is (protected) carboxyl; Q is lower alkylene; (m) is 0 or 1] or a pharmacologically acceptable salt thereof as an active ingredient. The compound of formula I is obtained, e.g. by reacting a compound of formula II or a salt thereof with a compound of formula III (X is a reactive residue; R<41> = R<4>). The agent is useful as a platelet agglutination inhibiting agent and employed for the prevention and treatment of thrombosis obstruction, myocartial, unstable angina pectoris, coronary contraction, asthma, nephritis, etc. The agent is administered in a dose of 0.01-50mg/body kg/day as the active ingredient.
The invention relates to physiological sampling during a predetermined activity. The present disclosure relates to a method for measuring one or more physiological signals during participation of a user in a predetermined activity. Exemplary predetermined activities may include activities such as walking, climbing stairs, riding bicycles, and the like. The physiological measurements may include, but are not limited to, heart rate signals. The physiological measurements may be affected by a predetermined activity, and thus the system may be configured to employ one or more criteria to minimize the impact prior to measuring the physiological information. The one or more criteria may include, but are not limited to, an inter-sample latency, a continuous motion criterion, a predetermined activity criterion, a post-physiological measurement amount of time, and a confidence value. The continuous motion criterion may be based on a predetermined type of activity. For example, walking may have a walking state criterion and a number of steps criterion.
Major depressive disorder (MDD) affects millions of individuals worldwide, leading to considerable social and economic costs. Despite advancements in pharmacological treatments, achieving remission remains a key challenge, with a substantial number of patients showing resistance to existing therapies. This resistance is often associated with elevated levels of proinflammatory cytokines, suggesting a connection between inflammation, MDD pathophysiology, and treatment efficacy. The observation of increased immune activation in about a quarter of patients with MDD resulted in the distinction between inflammatory and noninflammatory endotypes. Although anti-inflammatory treatments show promise in alleviating depression-like symptoms, responses are heterogeneous, thus highlighting the importance of identifying distinct inflammatory endotypes to tailor effective therapeutic strategies. The intestinal microbiome emerges as a crucial modulator of mental health, mediating its effects partially through different immune pathways. Microbiota-derived short-chain fatty acids (SCFAs) significantly impact innate and adaptive immune cells, regulating their differentiation, function, and cellular response. Furthermore, gut-educated immune cells reach the border regions of the central nervous system (CNS), regulating glial cell functions. Although the CNS modulates immune responses via efferent parts of the vagus nerve, afferent tracts concurrently transport information on peripheral inflammation back to the brain. This bidirectional communication is particularly relevant in depression, allowing for therapeutic stimulation of the vagus nerve in the context of inflammatory depression endotypes. In this review, we explore the intricate relationship between inflammation and depression, discuss how inflammatory signals are translated into depressive-like symptoms, and highlight immune-modulating therapeutic avenues.
INTRODUCTION: Umbilical hernia is common in patients with cirrhosis; however, there is a paucity of dedicated studies on postoperative outcomes in this group of patients. This population-based cohort study aimed to determine the outcomes after emergency and elective umbilical hernia repair in patients with cirrhosis.
METHODS: Two linked electronic healthcare databases from England were used to identify all patients undergoing umbilical hernia repair between January 2000 and December 2017. Patients were grouped into those with and without cirrhosis and stratified by severity into compensated and decompensated cirrhosis. Length of stay, readmission, 90-day case fatality rate and the odds ratio of 90-day postoperative mortality were defined using logistic regression.
RESULTS: In total, 22,163 patients who underwent an umbilical hernia repair were included and 297 (1.34%) had cirrhosis. More patients without cirrhosis had an elective procedure, 86% compared with 51% of those with cirrhosis (P < 0.001). In both the elective and emergency settings, patients with cirrhosis had longer hospital length of stay (elective: 0 vs 1 day, emergency: 2 vs 4 days, P < 0.0001) and higher readmission rates (elective: 4.87% vs 11.33%, emergency:11.39% vs 29.25%, P < 0.0001) than those without cirrhosis. The 90-day case fatality rates were 2% and 0.16% in the elective setting, and 19% and 2.96% in the emergency setting in patients with and without cirrhosis respectively.
CONCLUSION: Emergency umbilical hernia repair in patients with cirrhosis is associated with poorer outcomes in terms of length of stay, readmissions and mortality at 90 days.
Subjects will be exposed to ultrafine particles for three hours in an exposure chamber. During that time participants will perform intermittent bicycle ergometer training. Training intensity is adjusted individually to increase ventilation to 20 l/min/m². During exposure, heart rate will be monitored continuously via ECG. Blood pressure will be measured every 15 minutes. Ultrafine elemental carbon black particles are generated using a commercially available electric spark generator. Particle number, mass, and size distribution will be monitored during exposure.
A vaginal douche bottle with a composition of ingredients to tighten and prevention of growth of bad microorganisms in reproductive organs of human is provided. The vaginal douche bottle includes a removable cap, a middle portion, a bottom portion, and threads. The removable cap is adapted to remove from the vaginal douche bottle when a pipe adapter is required to be coupled with the vaginal douche bottle. The middle portion allows a user to hold the vaginal douche bottle. Threads are grooved on a top portion of the vaginal douche bottle to couple with a lower portion of the pipe adapter. The composition of ingredients filled in the vaginal douche bottle. When the middle portion of the vaginal douche bottle is pressed, the composition of ingredients comes out from the vaginal douche bottle through the adapter pipe and cleans the reproductive organs of the user.
The recommended initial total daily dosage of the oral solution for children is 0.3 to 0.4 mg/kg administered in four divided doses. The following table provides an approximate initial daily dosage recommendation for children.

These pediatric schedules are the best approximation of an average dose recommendation which may be adjusted downward according to the overall nutritional status and degree of dehydration encountered in the sick child. Reduction of dosage may be made as soon as initial control of symptoms has been achieved. Maintenance dosage may be as low as one-fourth of the initial daily dosage. If no response occurs within 48 hours, diphenoxylate hydrochloride and atropine sulfate is unlikely to be effective.

KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.
The invention relates to a novel peroxynitrite (ONOO)  ‑  ) The preparation of the fluorescent probe and the accurate detection of the fluorescent probe in the process of drug-induced liver injury formation and inhibition are carried out, wherein the name of the compound probe is 6,8-dichloro-9,9-dimethyl-7-oxo-7,9-dihydroacridine-2-diphenyl phosphate (6,8-dichoro-9,9-dimethyl-7-oxo-7,9-diazeparidin-2-yldiphenylphosphinate). The compound molecular sensor of the invention can efficiently, sensitively and selectively detect the ONOO in organisms  ‑  . The probe is not interfered by other ROS and RNS analogues, and can be efficiently and sensitively used in complex environmentQuantitative detection of difficult-to-capture ONOO in biological systems  ‑  The content of (a). And is used for detecting living organisms such as cells or animals with excellent biocompatibility. The probe molecules were applied to APAP-induced model mice and the induced lesions were treated with inhibitors (GSH, glu, NAC). The molecule can realize accurate imaging in the formation and inhibition process of drug-induced liver injury. The method is beneficial to early diagnosis of patients with liver injury and screening of treatment schemes, and has important practical significance.
Arm1: Non-treatment Model Building. Up to 700 children will be recruited from 5 cochlear implant programs in the United States. Children will be enrolled and followed for up to four years after implantation. Study information will be obtained from each child's medical record before and after implantation including cause of hearing loss, general health, language and communication history, family history, cochlear implant device and surgery. Audiological information before and after implantation will be collected from routine visits that are part of cochlear implant candidacy evaluation and audiology evaluations after implantation. This includes audiology evaluations after activation of the cochlear implant that take place at around 6, 12, 18, 24, 36 and/or 48 months. Pre-surgical MRI done at each participating site as part of routine pre-operative evaluation will also be collected for analysis. If enrolled into the study at Lurie Children's Hospital of Chicago before the pre-surgical MRI is done, the parent or guardian will have the option to have their child undergo additional research scans during the pre-surgical MRI.

Parents will be asked to complete baseline and follow-up surveys. The surveys will ask about family demographic and health information, language exposure in the home, therapy and school services, and language and communication ability of the child. Parental surveys will be readministered at about 12-month intervals after the child's device is turned on. In addition, surveys about the child's cognition will be sent to parents after their child has used their implant for one and two years. Surveys will be offered online by a secure link provided during clinical visits, emailed after the visit or sent by MyChart to the parent/guardian for completion at home.

An in-person research-only speech and language evaluation will be done at about one-year intervals after initial implantation during each year the child is enrolled in the study. The evaluation will take less than two hours.

Arm 2: Communication Treatment. In addition to all of the study procedures described above for Arm1, at only Lurie Children's Hospital of Chicago, 10 children will be enrolled in each of four years who meet additional inclusion criteria. Children enrolled in this arm will receive Parent Implemented Communication Treatment (PICT). PICT involves training parents to use communication skills to support development of their child's language. PICT will consist of one-hour weekly sessions for about six months provided virtually by a secure video chat system such as Zoom. The child and parent/caregiver will both participate in each weekly session. In addition, parent and child social interactions will be evaluated by video chat each month for six months and then annually for two years. The parent and child social interaction evaluation will take less than 15 minutes. Children who receive PICT will continue to receive all other therapies. In other words, no therapies will be discontinued during the time children are receiving PICT.
This study aims to quantitatively analyze the distribution of encapsulated nerve endings in the human thumb interphalangeal (IP) joint capsule. There are three types of nerve endings. Type-I nerve endings (Ruffini-like ending) sense pressure changes, Type II (Pacini-like ending) nerve endings contribute to the kinesthetic sense, and Type III (Golgi-like ending) nerve ending provides proprioceptive information. We dissected five right thumbs IP joints from freshly frozen cadavers (5 men). The mean age of the cadavers at the time of death was 63.4 years (55-73). Sections were stained with the hematoxylin-eosin and antiprotein gene product 9.5 (PGP9.5) to identify encapsulated nerve endings. Transverse sections were cut and divided into volar, dorsal, and then into two equal parts, proximal and distal. The density of encapsulated nerve endings compared to volar versus dorsal and proximal versus distal regions was examined. This study showed that type 1 nerve endings were more common in the distal parts of the IP joint (p < 0.05). Also, type 3 nerve endings were observed in the thumb IP joint. There was no difference between regions in type II and type III nerve endings. The current study demonstrates that the distribution of encapsulated nerve endings in the IP joint is different from the PIP and DIP joints. Moreover, further studies are required to understand the thumb's physiology.
This utility model relates to the composition of stable, water-dispersed nanoparticles of ionic polymers - synthetic (e.g. polyacrylic or polymethacrylic) or natural (e.g. hyaluronic) polyacid, and the natural biologically active substance berberine chloride, which has antioxidant, anti-bacterial, and antitumor properties. The resulting water dispersions do not contain an organic solvent, which makes them suitable for oral and external use by people of all ages. The efficiency and load capacity of berberine chloride in nanoparticles are high. The resulting water dispersions of nanoparticles have proven antioxidant and in vitro antitumor properties and can find application in medicine, pharmacy, food industry, cosmetics and so forth.
FIELD: medicine, pharmacy. SUBSTANCE: invention relates to a pharmaceutical composition used for treatment of Parkinson's disease and Parkinson's syndromes. Pharmaceutical composition contains in pharmaceutically acceptable medium at least rilusol or at least one of its pharmaceutically acceptable salts. Invention relates also to method for preparing such composition and to method for treatment of Parkinson's disease and Parkinson's syndromes that involves administration to patient the indicated composition. Invention provides expansion of medicinal agents used for treatment of Parkinson's disease and Parkinson's syndromes. EFFECT: enhanced effectiveness of treatment, valuable medicinal properties of composition. 22 cl, 1 tbl
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

In two randomized, multicenter, prospective vehicle-controlled clinical trials, subjects with moderate plaque psoriasis of the body applied betamethasone dipropionate spray or vehicle spray twice daily for 4 weeks. A total of 352 subjects applied betamethasone dipropionate spray and 180 subjects applied vehicle spray.

Adverse reactions that occurred in at least 1% of subjects treated with betamethasone dipropionate spray for up to 28 days are presented in Table 1.

Less common adverse reactions (with occurrence lower than 1% but higher than 0.1%) in subjects treated with betamethasone dipropionate spray were application site reactions including telangiectasia, dermatitis, discoloration, folliculitis and skin rash, in addition to dysgeusia and hyperglycemia. These adverse reactions were not observed in subjects treated with vehicle.
Topical application of matched Placebo to BF-200 ALA gel (without containing active ingredient) ). Application of a 1 mm thick layer covering each lesion and a 0.5 cm to 1 cm surrounding margin.
Remifentanil-induced hyperalgesia (RIH) represents a significant clinical challenge due to the widespread use of opioids in pain management. However, the molecular and cellular mechanisms underlying RIH remain elusive. This study aimed to unravel the role of spinal cord microglia, focusing on the Nrf2/HO-1 signaling pathway and TRPV4 channels in the development of RIH. We used both in vivo and in vitro models to investigate the activation state of spinal cord microglia, the expression of TRPV4 channels, and the modulation of the Nrf2/HO-1 pathway under remifentanil exposure. In addition, we evaluated the potential therapeutic effects of dexmedetomidine, a perioperative α2-adrenergic agonist, on RIH and its related molecular pathways. Our results revealed a prominent role of spinal cord microglia in RIH, demonstrating an apparent microglial M1 polarization and increased TRPV4 channel expression. A notable observation was the downregulation of the Nrf2/HO-1 pathway, which was associated with increased neuroinflammation and mechanical allodynia. By upregulating or overexpressing Nrf2, we confirmed its ability to inhibit TRPV4 and thereby attenuate RIH-associated mechanical allodynia, M1 polarization, and neuroinflammation. Encouragingly, dexmedetomidine demonstrated therapeutic potential by positively modulating the Nrf2-TRPV4 nexus, attenuating mechanical allodynia, and reducing microglial inflammation. Our research highlights the critical role of spinal cord microglia in RIH mediated by the Nrf2-TRPV4 axis. The ability of dexmedetomidine to modulate this axis suggests its potential as an adjunctive therapy to remifentanil in mitigating RIH. Further studies are imperative to explore the broader implications and practical applicability of our findings.
A comprehensive utilization method for low-grade tea leaves is provided. The low-grade tea leaves are adopted as raw materials of the method. The method includes removing impurities, dipping to separate polysaccharides, crystallizing, drying, dipping to separate tea polyphenols, crystallizing, drying and drying tea leaf dregs. The step of dipping to separate the tea polysaccharides is performed by dipping with water at maintained temperature, filtering, subjecting filtrate to vacuum distillation, concentrating, allowing the product to stand in an ice water bath, crystallizing to obtain the tea polysaccharides, and drying with a drying oven. The step of dipping to separate the tea polyphenols is performed by dipping filter dregs with water at maintained temperature, filtering, adding filtrate to an evaporating dish, evaporating, crystallizing, filtering and drying obtained crystals with the drying oven to obtain a tea polyphenol finished product. The tea leaf dregs are dried with a drying oven or aired, smashed, sealed, packaged and used for preparing pillow inners. The tea polysaccharides and the tea polyphenols are extracted through the method from the low-grade tea leaves, and the rest tea leaf dregs are dried and prepared into the pillow inners, thus achieving full use of the low-grade tea leaves and greatly increasing the added value of the tea leaves.
PURPOSE: A composition is provided to prevent and improve allergic diseases by suppressing the production of IgE and IgG and the secretion of histamine. CONSTITUTION: A food composition comprises 100 parts by weight of acanthopanax senticosus extracts and 50-150 parts by weight of prunellavulgaris extracts. The food composition has anti-histamine activity. The extracts are hot water extracts. The allergic disease is at least one selected from a group consisting of atopic dermatitis, allergic rhinitis, asthma, allergic conjunctivitis, allergic enterocolitis, anaphylaxis and urticaria. The extracts are manufactured by adding ethanol to the hot water extracts of acanthopanax senticosus and prunellavulgaris and obtaining from the precipitation. [Reference numerals] (AA) Example 1; (BB) Example 2